AKESO Aktie

 

There was HKD1.2 billion, HKD772 million and HKD278.2 million Southbound Trading net inflow to BABA-W (09988.HK), AKESO (09926.HK) and MEITUAN-W (03690.HK).There was HKD784.6 million, HKD493 million and HKD487.4 million Southbound Trading net outflow from SMIC (00981.HK), YOFC (06869.HK) and XIAOMI-W (01810.HK).For Southbound Tr......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

AKESO (09926.HK) proposed to place 20 million shares at a placing price of HKD97.76 per share, representing a discount of approximately 6.9% to the closing price of HKD105 per share as quoted on the Stock Exchange on the last full trading day (13th) prior to the date of the placing agreement.The placing shares represent approxim......

AKESO (09926.HK) announced a plan to place 20 million new shares at HKD97.76 per share. The placing shares represent approximately 2.13% of the enlarged issued share capital. The placing price represents a discount of approximately 6.9% to yesterday's (13th) closing price of HKD105.Assuming the placing is fully completed, gross ......

HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in......

CLSA published a research report stating that China's healthcare sector has recently completed four major business development (BD) and collaboration deals in succession. The four deals involve HENGRUI PHARMA (01276.HK) and Novo Nordisk A/S (NVO.US), AKESO (09926.HK) and AstraZeneca PLC Ordinary Shares (AZN.US), Regeneron Pharma......

BofAS published a research report stating that three recent collaborations in China's pharmaceutical/biotechnology sector have strengthened sector momentum. The broker raised the TP for SBP GROUP (01177.HK) from HKD7.3 to HKD7.4 and reiterated its "Buy" rating. It also maintained the "Buy" rating and HKD136 TP for AKESO (09926.H......

There was HKD1.4 billion, HKD178.8 million and HKD166.7 million Southbound Trading net inflow to TENCENT (00700.HK), WUXI BIO (02269.HK) and MINIMAX-W (00100.HK).There was HKD971.4 million, HKD145.9 million and HKD17.2 million Southbound Trading net outflow from SMIC (00981.HK), Z.AI (02513.HK) and AKESO (09926.HK).For Southboun......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Daiwa released a research report stating that AKESO (09926.HK)'s global partner Summit Therapeutics Inc. (SMMT.US) announced on Monday evening (28 Sep, US Eastern Time) that it had signed an agreement with AstraZeneca PLC Ordinary Shares (AZN.US), under which AstraZeneca will make a strategic equity investment of USD2 billion in......

Nomura said in a report that AKESO (09926.HK)'s overseas partner Summit Therapeutics Inc. (SMMT.US) announced before the Hong Kong stock market open on September 29 that it had secured a USD2 billion strategic investment from AstraZeneca PLC Ordinary Shares (AZN.US). The broker maintained its Buy rating on AKESO and its TP at HK......

There was HKD383.5 million, HKD162.4 million and HKD75.5 million Southbound Trading net inflow to XIAOMI-W (01810.HK), Z.AI (02513.HK) and KB LAMINATES (01888.HK).There was HKD575.6 million, HKD568.1 million and HKD551.6 million Southbound Trading net outflow from AKESO (09926.HK), SMIC (00981.HK) and BABA-W (09988.HK).For South......

Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm's flagship cancer drug, while a new deal from US giant Merck further underscored the sector's global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso's immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

AKESO (09926.HK)'s overseas partner Summit Therapeutics Inc. (SMMT.US) received an investment from AstraZeneca (AZN.US), which is boon to the global development of ivonescimab, CLSA said in a research report. The broker noted that AstraZeneca announced on Monday (28th) a USD2 billion preferred share investment in Summit Ther......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

At midday close, HSI dropped 155 pts or 0.6% to 24,486. HSTI dropped 58 pts or 1.4% to 4,237. HSCEI fell 50 pts or 0.6% to 8,166.Active Heavyweights:XIAOMI (01810.HK) closed at $25.14, down 2.8%BABA (09988.HK) closed at $105.3, down 2.2%TENCENT (00700.HK) closed at $433, down 1.5%MEITUAN (03690.HK) closed at $70.8, down 1.5%CCB ......

AstraZeneca PLC Ordinary Shares (AZN.US) has made a strategic USD2 billion investment in Summit Therapeutics Inc. (SMMT.US). AKESO (09926.HK) surged 12.6% in early trading today (29th), reaching HKD103.6, the highest level in more than one month. Turnover amounted to HKD1.396 billion.Reuters reported that AstraZeneca will subscr......

HONG KONG, Sep. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4......

Despite mounting US interest rates, China's biopharmaceutical sector remained resilient in late September across the Hong Kong and mainland China markets, supported by policy measures and prospects for out-licensing, HSBC Global Investment Research said in a report.2026 will be a harvest year for China's innovative drug ......